Studies on the Influence of Long-Acting Insulin Analogs on Cancer Risk Should Be Based on the New-User Design Only
J Clin Oncol
.
2018 Mar 10;36(8):829-830.
doi: 10.1200/JCO.2017.76.8721.
Epub 2018 Jan 25.
Authors
Philippe Autier
1
,
Maria Bota
1
,
Alice Koechlin
1
,
Peter Boyle
1
Affiliation
1
Philippe Autier, Maria Bota, Alice Koechlin, and Peter Boyle, International Prevention Research Institute, Lyon, France.
PMID:
29369705
DOI:
10.1200/JCO.2017.76.8721
No abstract available
Publication types
Letter
Comment
MeSH terms
Breast Neoplasms*
Diabetes Mellitus, Type 2*
Female
Humans
Hypoglycemic Agents
Incidence
Insulin, Long-Acting
Substances
Hypoglycemic Agents
Insulin, Long-Acting